SEC Tracker
Get the app

Repligen RGEN

On November 13, 2025, Repligen Corp (RGEN) director Jane Doe purchased 10,000 shares of the company's stock for a total transaction value of $500,000. This insider buying activity signals a bullish sentiment from a key decision-maker and may indicate positive future prospects for the company.

Anthony Hunt, insider filing for RGEN

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Repligen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.